4 research outputs found
Tirsi, egloga boschereccia tragicomica, del Trapolini : nella quale oltre le allegorie poste nel fin dell'opera vi sono anco interposti gli argomenti, ouer sommarij Ă ciascun'atto, & altre cose notabili : con l'interuento di vn'Echo doppio, cosa non meno piaceuole, che morale, & accommodata ad ogni stato di persone, hora in luce data.
Marca tip. en port. (Zappella, 69).Sign.: A-L8, [M]2.Hojas imp. por ambas caras.Capitulares grab. xil.Il. xil
ALLiance for sEcondary PREvention after an acute coronary syndrome. The ALLEPRE trial: A multicenter fully nurse-coordinated intensive intervention program
The main objective of cardiovascular disease prevention is to reduce morbidity and mortality by promoting a
healthy lifestyle, reducing risk factors, and improving adherence to medications. Secondary prevention after an
acute coronary syndrome has proved to be effective in reducing new cardiovascular events, but its limited use
in everyday clinical practice suggests that there is considerable room for improvement. The short-term results
of evidence-based studies of nurse-coordinated secondary prevention programs have been positive, but there
is a lack of long-term outcome data. The Alliance for the Secondary Prevention of Cardiovascular Disease in the
Emilia-Romagna region (ALLEPRE) is a multicenter, randomized, controlled trial designed to compare the effects
of a structured nurse-coordinated intensive intervention on long-term outcomes and risk profiles after an acute
coronary syndrome with those of the standard of care. All of the patients randomized to the intervention group
take part in 9 one-to-one sessions with an experienced nurse fromthe participating centerswith the aimat promoting
healthy lifestyles, reducing risk factors, and increasing adherence to medication over a mean period of 5
years. The primary clinical end point is the reduction in the risk of the 5-year occurrence of major adverse events
(a composite of cardiovascular mortality, nonfatal reinfarction, and nonfatal stroke). The primary surrogate end
point is the achievement of prespecified targets relating to classical risk factors, lifestyle modifications, and adherence
to pharmacological therapy after 2 years of follow-up